Epicrispr Biotechnologies
CompanyUnited States
Epicrispr Biotechnologies develops 2 assets, the furthest in phase 2 (EPI-321 in facioscapulohumeral muscular dystrophy). Mostly gene therapy acting on epigenetic regulation of gene expression and DUX4; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 2
- Raised
- US$158m
- 1
- Grant
- 0
- Trials
- 1
- Signal
Pipeline
2AAV-delivered epigenetic modulation silences DUX4 expression without altering the underlying DNA sequence.
Phase 2, Gene therapy, Epigenetic regulation of gene expression, DUX4, facioscapulohumeral muscular dystrophy
CRISPR-based epigenome editing provides a mutation-agnostic approach to treating Duchenne muscular dystrophy.
Stage not known
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Funding rounds and grants2
- People24
- Signals1
- Similar companies6